NCT01044303View on ClinicalTrials.gov

Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Transplant; Failure, Kidney
Interventions
DRUG

Myfortic Escalation

Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.

Trial Locations (1)

27834

East Carolina University, Greenville

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

East Carolina University

OTHER